Close Menu

financial guidance

Mass cytometry revenues increased 28 percent to $17.5 million year over year, but microfluidics revenues dropped 16 percent to $10.7 million.

The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.

The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.

The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.

Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.

The company's Q2 revenues came in above previously reported preliminary revenues of $835 million, but fell short of the analysts' estimate of $866.2 million.

The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.

Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.

Qiagen reported year-over-year net sales of 1 percent, or 5 percent at constant exchange rates ahead of its planned Q2 earnings release next week.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.